ArticleClinical and experimental immunology2020

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.

M P Petrova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.